{
    "clinical_study": {
        "@rank": "67203", 
        "acronym": "GETUG-AFU22", 
        "arm_group": [
            {
                "arm_group_label": "Radiation", 
                "arm_group_type": "Active Comparator", 
                "description": "Pelvic radiotherapy\n46 Gy in 23 fractions of 2 Gy.\nprostate only-boost up to 66 Gy"
            }, 
            {
                "arm_group_label": "Radiation and Degarelix", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy:\n46 Gy in 23 fractions of 2 Gy.\nprostate only-boost up to 66 Gy\nAssociated with hormonal therapy by degarelix:\nbeginning in parallel to radiotherapy for 6 months\nFirst dose of 240 mg\nMaintenance dose of 80 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to select the best therapeutic strategy in studying the\n      effectiveness of the association of a short duration hormonal therapy and radiotherapy\n      compared with radiotherapy alone, in patients with a detectable PSA after radical\n      prostatectomy."
        }, 
        "brief_title": "Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy", 
        "completion_date": {
            "#text": "June 2025", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenocarcinoma of Prostate", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study the effectiveness of the association of a short duration hormonal therapy by degarelix\n      (Firmagon \u00ae) and radiotherapy, with radiotherapy alone on survival without events in the\n      treatment of detectable PSA after radical prostatectomy.\n\n      122 patients should be included over a period of 2 years. Patients will be treated according\n      to the following scheme:\n\n        -  Arm A (61 patients) : Pelvic Radiotherapy: 46 Gy and prostate only boost up to 66 Gy\n\n        -  Arm B (61 patients) : Arm A + hormonal therapy by degarelix during 6 months"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient with localized prostate adenocarcinoma treated with radical prostatectomy\n             (whatever the initial prognostic stage)\n\n          2. R0 or R1\n\n          3. pN0 or pNx\n\n          4. Post prostatectomy PSA \u2265 0,2 ng/mL measured between 1 month and 4 months after\n             surgery and increasing to a second test performed between 1 et 8 month after the post\n             prostatectomy dosage\n\n          5. PSA \u2264 2 ng/mL at moment of the randomisation\n\n          6. No clinical signs of progressive disease (bone scan or PET scan or  abdominal and\n             pelvic scan or  MRI): N0, M0\n\n          7. Neutrophils \u2265 1500/mm3; platelet count \u2265 100 000/mm3\n\n          8. Bilirubin \u2264 ULN; ALP, AST et ALT \u2264 1,5 ULN\n\n          9. Creatinine < 140 \u00b5mol/L (or  clearance > 60mL/min)\n\n         10. Normal fasting glucose\n\n         11. ECOG \u2264 1\n\n         12. Age > 18 years\n\n         13. Life expectancy \u2265 10 years\n\n         14. Patients with invasive cancer in complete response for more than five years are\n             eligible\n\n         15. Patients who have received the information sheet and signed the informed consent form\n\n         16. Patients with a public or a private health insurance coverage\n\n        Exclusion Criteria:\n\n          1. Prostate cancer histology other than adenocarcinoma\n\n          2. Patients pN1, N1 and M1\n\n          3. History of pelvic radiotherapy\n\n          4. Contraindication to pelvic irradiation (eg, scleroderma, chronic inflammatory bowel\n             disease, etc.).\n\n          5. Testosterone \u2264 0,5 ng/mL\n\n          6. History of surgical castration\n\n          7. Previous treatment by hormonotherapy\n\n          8. Antineoplastic treatment in progress\n\n          9. History of another invasive cancer within 5 years before inclusion (with the\n             exception of a basal cell skin carcinoma treated)\n\n         10. Known pituitary adenoma\n\n         11. Severe hypertension uncontrolled by appropriate treatment (160 mm Hg systolic and /\n             or 90 mm \u200b\u200bHg diastolic)\n\n         12. Patient with a corrected QT interval (using Fridericia correction) greater than 450\n             msec\n\n         13. Individual deprived of liberty or placed under the authority of a tutor\n\n         14. Unable to undergo medical monitoring test for geographical, social or psychological\n             reasons\n\n         15. Known hypersensitivity to the treatment in test\n\n         16. Administration of an investigational therapeutic within 28 days prior to the\n             screening visit or more if treatment is likely to influence the outcome of this"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994239", 
            "org_study_id": "UC-0160/1204"
        }, 
        "intervention": [
            {
                "arm_group_label": "Radiation and Degarelix", 
                "description": "First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)", 
                "intervention_name": "Degarelix", 
                "intervention_type": "Drug", 
                "other_name": "Firmagon"
            }, 
            {
                "arm_group_label": [
                    "Radiation", 
                    "Radiation and Degarelix"
                ], 
                "description": "46 Gy in 23 fractions Prostate only-boost up to 66 Gy", 
                "intervention_name": "Pelvic Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate-Specific Antigen", 
            "LHRH antagonist", 
            "Radiotherapy"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "link": {
            "description": "Site UNICANCER", 
            "url": "http://www.unicancer.fr"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "Institut Bergonie"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "laurent.solomon@hmn.aphp.fr", 
                    "last_name": "SALOMON Laurent", 
                    "phone": "01 49 81 25 53"
                }, 
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Hopital Henri Mondor"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jf.berdah@wanadoo.fr", 
                    "last_name": "Jean F. Berdah, MD", 
                    "phone": "33-4-9412-5555"
                }, 
                "facility": {
                    "address": {
                        "city": "Hyeres", 
                        "country": "France", 
                        "zip": "83400"
                    }, 
                    "name": "Clinique Sainte-Marguerite"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06088"
                    }, 
                    "name": "Centre Antoine Lacassagne"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nimes", 
                        "country": "France", 
                        "zip": "30029"
                    }, 
                    "name": "Chu Caremeau"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "51056"
                    }, 
                    "name": "Institut Jean Godinot"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy", 
        "overall_contact": {
            "email": "m-habibian@unicancer.fr", 
            "last_name": "Muriel Habibian", 
            "phone": "+33 1 76 64 78 07"
        }, 
        "overall_official": [
            {
                "affiliation": "CHU Poitiers", 
                "last_name": "St\u00e9phane Gu\u00e9rif", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Henri Mondor", 
                "last_name": "Laurent Salomon", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Biochemical recurrence was defined as a PSA > nadir + 0.4 ng / mL confirmed by a second PSA> nadir + 0.4 ng / mL in elevation.", 
                "measure": "Survival without biological event", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "The clinical recurrence will be defined by the discovery of a local recurrence in rectal examination, the appearance of metastases by imaging or biopsy, or clinical manifestation associated with malignant disease without elevated PSA but with histological documentation or imaging.", 
                "measure": "Survival without clinical event", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Survival without metastases", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "according CTC-AE v4.0", 
                "measure": "Acute and late toxicities of the association of hormone therapy with radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "according CTC-AE v4.0", 
                "measure": "Toxicities of radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "QLQ-C30, QLQ-PR25 and IPSS", 
                "measure": "Quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 years after the end of the radiotherapy"
            }, 
            {
                "measure": "kinetics of testosterone", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months after the end of the radiotherapy and after biological release"
            }
        ], 
        "source": "UNICANCER", 
        "sponsors": {
            "collaborator": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "UNICANCER", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}